Potassium Exchange Resins - Pharmacology

1. Introduction and Clinical Context

2. Why Are They Important for Dialysis Patients?

• Dialysis patients are prone to hyperkalemia due to absent/reduced urinary potassium excretion
• Dietary potassium restriction alone is often insufficient
• Dialysis removes potassium, but only during sessions - hyperkalemia can build up between sessions
• Potassium exchange resins provide ongoing, between-dialysis potassium control
• They are also used in patients where dialysis is being initiated, delayed, or in outpatient CKD management

3. The Three Main Potassium Exchange Resins

3.1 Sodium Polystyrene Sulfonate (SPS) - Kayexalate

• Constipation (most common)
• Nausea, vomiting
• Hypomagnesemia, hypocalcemia (due to non-selective binding)
• Sodium loading (1 g contains ~100 mg Na⁺) - important in heart failure and fluid-overloaded patients
• Intestinal/colonic necrosis - a serious, potentially fatal complication; risk increased when given with sorbitol (previously co-administered as a laxative)

3.2 Patiromer (Veltassa)

• No sodium load (important in dialysis/heart failure patients)
• Lower risk of intestinal necrosis
• Can decrease potassium for at least a year of use
• Effective in patients with diabetic renal disease and patients on RAAS inhibitors (ACE inhibitors, ARBs, MRAs - drugs that cause hyperkalemia but are beneficial for cardiac/renal protection)

• Constipation (major side effect)
• Hypomagnesemia (Ca²⁺ is exchanged - free Mg²⁺ can also be displaced)
• Nausea, abdominal discomfort, diarrhea, flatulence
• Drug interactions: No other medication should be taken within 3 hours before or after patiromer (it can bind other drugs and reduce their absorption)

3.3 Sodium Zirconium Cyclosilicate (SZC) - Lokelma

• SZC is technically a zirconium silicate crystal with pores that are sized to trap K⁺ ions selectively, like a molecular sieve - it is not a classic polymer resin
• Its fast onset (1 hour) makes it potentially useful even in emergency department settings
• Acts throughout the entire GI tract (not just colon)
• Has been shown effective as an adjunct to insulin + glucose therapy for acute hyperkalemia

• Edema (sodium loading: a 5g dose contains ~400 mg Na⁺ - relevant for dialysis patients)
• Hypokalemia if overused
• GI effects generally mild

4. Comparison Table

5. Mechanism of Action - Simplified Diagram (Concept)

[Intestinal Lumen - High K⁺ in CKD/ESRD patient]
        ↓
[Exchange Resin is administered]
        ↓
Resin (carries Na⁺/Ca²⁺/H⁺) + K⁺ in gut fluid
        ↓
K⁺ binds to resin → Resin releases Na⁺/Ca²⁺/H⁺
        ↓
[Resin + bound K⁺ passes through gut → FECES]
        ↓
Serum K⁺ falls (as K⁺ moves from blood into gut to maintain equilibrium)

6. Place in the Hyperkalemia Management Algorithm

In severe hyperkalemia (K⁺ > 7.0 mEq/L) or with ECG changes, emergent hemodialysis is the most effective and fastest definitive treatment - cation-exchange resins are too slow for this scenario. - Katzung's Basic and Clinical Pharmacology, 16th Ed.

7. Special Considerations in Dialysis Patients

1. Sodium load: SPS and SZC add sodium to the body - problematic in anuric dialysis patients who cannot excrete extra sodium (risk of fluid overload and hypertension). Patiromer is preferred in these patients.
2. Between-session hyperkalemia: Resins are used between dialysis sessions to control potassium buildup. Patients are often counseled on a low-potassium diet alongside resin therapy.
3. RAAS inhibitor continuation: A key benefit of patiromer and SZC is that they allow patients to continue taking ACE inhibitors, ARBs, and aldosterone antagonists (which cause hyperkalemia but protect the kidneys and heart) - the resin manages the resulting hyperkalemia.
4. Intestinal necrosis risk with SPS: In critically ill or post-operative dialysis patients, SPS (especially with sorbitol) should be used cautiously due to this serious complication.
5. Dialysate potassium: Dialysis itself uses a low-potassium dialysate (0-4 mEq/L) to pull K⁺ across the membrane. Resins complement this by reducing the interdialytic K⁺ burden.

8. Pharmacokinetics Summary

• All three resins are NOT systemically absorbed - they act entirely within the GI lumen
• They are excreted in the feces along with the bound potassium
• No renal dosage adjustment is required (ironic, but relevant - they work locally, not systemically)
• Onset varies greatly: SZC (1h) > SPS (2-24h) > Patiromer (7h)

9. Key Points for Exam

• Potassium exchange resins lower K⁺ by GI elimination, not renal excretion - this is why they work even in dialysis/anuric patients
• SPS (oldest), Patiromer (2015), SZC/Lokelma (2018) - know the FDA approval timeline
• SPS exchanges Na⁺; Patiromer exchanges Ca²⁺; SZC exchanges Na⁺/H⁺ - these determine side effects
• Intestinal necrosis is the most feared side effect of SPS (especially with sorbitol)
• Hypomagnesemia is the classic metabolic side effect of Patiromer
• Drug interaction window (3 hours) is unique to Patiromer
• In dialysis patients, none of these resins replace emergent dialysis for severe/acute hyperkalemia
• SZC has the fastest onset (1 hour) and highest selectivity

• Katzung's Basic and Clinical Pharmacology, 16th Ed. - Chapter 15 (Diuretics & Hyperkalemia)
• Goldman-Cecil Medicine - Chronic Treatment of Hyperkalemia
• Tintinalli's Emergency Medicine - Hyperkalemia Treatment
• Frontiers: Systematic review of potassium exchange resins in CKD (2023)
• PMC: Potassium-Binding Agents for Hyperkalemia